Breast Cancer Treatment Milestones

Join Our Community of Science Lovers!

This story is a supplement to our feature "New Breast Cancer Treatments Help Sufferers Gain Ground" which was printed in the June 2008 issue of Scientific American.

Doctors started aggressively treating breast cancer in the 19th century, with the first mastectomy performed in 1882. But insights into mechanisms driving the disease that would lead to increasingly targeted therapies began with discoveries in the 1950s.

1880s–1890s

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

Hormonal cancer connection suggested when physicians report significant regression of breast cancer tumors following ovary removal or onset of menopause.
1896: First ovary removal performed as a breast cancer treatment by George T. Beatson.

1950s–1960s

1951: Estrogen and testosterone found to drive the growth of breast and prostate cancers, respectively.
1958: Cancer researchers identify additional “growth factor” proteins that help tumors thrive.
1966: Estrogen receptor identified.

1970s–1980s

1976: Cancer-promoting “oncogenes” first discovered in mammals.
1976: Clinical trials begin to show that lumpectomy with radiation can be as effective as mastectomy.
1977: Hormone-blocking drug tamoxifen approved in U.S. for treatment of breast cancers sensitive to estrogen or progesterone.
1988: Trial results show that preoperative chemotherapy shrinks tumors, making less invasive surgeries possible.

1990s–2008

1994: BRCA1 gene, known to increase susceptibility to breast cancer, is isolated.
1997: Letrozole, which blocks estrogen synthesis, approved in U.S. for patients whose cancer did not respond to tamoxifen.
1998: Trastuzumab, the first molecular-targeted cancer therapy, approved in U.S. for use in breast cancer.
2007: Lapatinib, an inhibitor of growth signaling, approved in U.S. for use in breast cancer.
2008: Bevacizumab, an inhibitor of blood vessel formation in tumors, approved in U.S. for use in breast cancer.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American